Pluristem Therapeutics (NASDAQ: PSTI) is an Israeli firm engaged within the improvement of human placental adherent stromal cells for business use in illness therapy.
They’ve developed a proprietary bioreactor system which gives a 3 dimensional (3D) micro-environment for his or her cells that resembles the setting within the human physique. Because of this, the cells develop quickly and stay wholesome and potent as they alter circumstances throughout the bioreactors to rework them into distinctive, patented cell remedy merchandise. The superior manufacturing know-how can generate cell merchandise on a mass scale with batch-to-batch consistency, making them true business merchandise.
The PLX Bioreactor system is built-in into an automatic and aseptic cell manufacturing facility, by which they will manufacture massive portions of cells of the very best high quality in an economical, reproducible and constant method. This functionality is important for any cell remedy to change into a real business product. Pluristem’s manufacturing website is positioned within the MATAM industrial park in Haifa, Israel, and is supplied with 500m2 clear rooms with the capability to fabricate cells to assist scientific trials and preliminary business wants upon reaching advertising approval.
